Danny Benjamin, MD, HS’98-’01, PhD, has been named a recipient of a 2026 Distinguished Faculty Award by the Duke Medical Alumni Association in recognition of his transformative leadership in pediatric clinical research, his national impact on child health, and his deep commitment to mentoring the next generation of investigators.
Benjamin serves as principal investigator and chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network (PTN), where he leads a global effort to design and execute clinical trials addressing critical gaps in evidence for off‑patent medicines used in children. Under his leadership, the PTN has established, or is actively determining, the correct dosing and safety of more than 100 of the most commonly used pediatric therapeutics. Each study is conducted under an Investigational New Drug application in collaboration with the U.S. FDA, contributing directly to pediatric labeling.
His research portfolio reflects exceptional breadth and impact. Benjamin has led multiple platform trials enrolling nearly 10,000 participants across diverse populations, including premature and term infants, breastfeeding mother–infant pairs, children from birth to age 18, children with obesity, and children receiving ECMO support. His long‑running POPS study, ongoing since 2010, continues to inform the pharmacokinetics and pharmacodynamics of essential medicines in children. Additional trials have addressed analgesics and pain medicines, anti‑seizure medications, antipsychotics, and therapeutics for adults with COVID‑19. These efforts have resulted in FDA labeling changes for more than a dozen molecules, directly improving the safety and effectiveness of treatments for children nationwide.
Equally distinguished is Benjamin’s legacy as a mentor. Recognized by the National Institutes of Health as a premier educator, he has built a research training environment that serves as a launching pad for early‑career scientists. More than 250 students, trainees, and junior physicians from around the world have used PTN data and resources and subsequently earned co‑authorship on peer‑reviewed publications.
Dr. Benjamin’s career is defined by scientific rigor, collaborative leadership, and a steadfast dedication to ensuring that children receive safe, evidence‑based, and appropriately dosed medicines — an impact felt at Duke, across the country, and around the globe.